Keytruda Dropped From England’s Cancer Drugs Fund For Bladder Cancer
Executive Summary
MSD said it was disappointed by the decision by the health technology assessment body, NICE, and that it was considering what further actions are available to ensure eligible patients with advanced bladder cancer continue to have access to its medicine.